TGF-β/TGF-β Receptor inhibitors |
Tyrosine kinase inhibitor |
LY-2152799 (Galunisertib) |
Fluorouracil/Capecitabine + Tumor specific mesorectal excision |
Locally Advanced Rectal Adenocarcinoma |
NCT02688712 (2016, Recruiting) |
Drug: LY2157299Drug: Capecitabine Drug: Fluorouracil Procedure: Tumor specific mesorectal excision |
|
|
|
Paclitaxel/Carboplatin |
Carcinosarcoma of the Uterus or Ovary |
NCT03206177 (2017, Recruiting) |
Drug: Galunisertib Drug: Paclitaxel Drug: Carboplatin |
|
|
|
Sorafenib |
Advanced Hepatocellular Carcinoma |
NCT02178358 (2014, Active, not recruiting) |
Drug: LY2157299 Drug: Sorafenib Drug: Placebo |
|
TGF-β receptor inhibitor |
TEW-7197 |
Pomalidomide |
Relapsed or Relapsed and Refractory Multiple Myeloma |
NCT03143985 (2017, Recruiting) |
Drug: TEW-7197 Drug: Pomalidomide |
EGF/EGFR inhibitors |
EGFR tyrosine kinase inhibitor |
Gefitinib |
Pemetrexed |
Advanced Non-Small Cell Lung Cancer |
NCT01982955 (2013, Active, not recruiting) |
Drug: Tepotinib Drug: Gefitinib Drug: Pemetrexed Drug: Cisplatin Drug: Carboplatin |
|
|
Icotinib |
Pemetrexed, Carboplatin |
III B/IV Non-Small Cell Lung Cancer |
NCT03151161 (2017, Not yet recruiting) |
Drug: Icotinib, Pemetrexed, Carboplatin Drug: Icotinib |
|
|
|
Cisplatin or Carboplatin |
metastatic non-squamous non-small cell lung cancer who did not progress after pemetrexed combined with platinum chemotherapy |
NCT03992885 (2019, Recruiting) |
Drug: Icotinib Drug: Cisplatin Drug: Carboplatin |
|
|
Apatinib |
Pemetrexed, Gemcitabine, Docetaxel |
NSCLC Patients Without T790M Mutation |
NCT03758677 (2018, Not yet recruiting) |
Drug: Apatinib Drug: Chemotherapy with platinum-based double drugs (Pemetrexed, Gemcitabine, Docetaxel) |
|
|
|
Pemetrexed Plus Carboplatin |
Advanced Non-small Cell Lung Cancer |
NCT03164694 (2018, Recruiting) |
Drug: Apatinib + Pemetrexed + Carboplatin Drug: Pemetrexed + Carboplatin |
|
|
Osimertinib |
Cisplatin or Carboplatin |
Metastatic EGFR Mutant Lung Cancers |
NCT03567642 (2018, Recruiting) |
Drug: Osimertinib Drug: Platinum Drug: Etoposide |
|
|
|
Platinum-based Doublet-Chemotherapy |
Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
NCT02151981 (2018, Active, not recruiting) |
Drug: Chemotherapy Drug: Cross-over to Osimertinib |
|
|
|
Pemetrexed + Cisplatin or Pemetrexed + Carboplatin |
Locally Advanced Non-Small Cell Lung Cancer |
NCT04035486 (2019, Recruiting) |
Drug: Osimertinib Drug: Osimertinib + Pemetrexed + Cisplatin Drug: Osimertinib + Pemetrexed + Carboplatin |
|
Monoclonal antibody |
Panitumumab |
Carboplatin and Paclitaxel |
Invasive Triple Negative Breast Cancer |
NCT02876107 (2016, recruiting) |
Drug: Carboplatin Other: Laboratory Biomarker Analysis Drug: Paclitaxel Biological: Panitumumab |
|
|
HLX07 |
Gemcitabine + Cisplatin/Paclitaxel + Carboplatin/mFOLFOX6 |
Advanced Solid Tumors |
NCT03577704 (2018, Recruiting) |
Drug: HLX07 + Gemcitabine + Cisplatin Drug: HLX07 + Paclitaxel + Carboplatin Drug: HLX07 + mFOLFOX6 |